Las Vegas, NV -- (SBWIRE) -- 10/11/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), MannKind Corporation (NASDAQ:MNKD), Amarin Corporation plc (ADR) (NASDAQ:AMRN), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) managed to keep its gain at 5.97% on below -normal volume of 8.63M shares. The stock settled at $10.82 after floating in a range of $10.40 to $10.90. Its latest price has reached market capitalization of $1.83 billion. Its 52-week range has been $1.77 to $11.49. Himax Technologies, Inc. operates as an IC design house with LCD manufacturing capability. The Company focuses on display IC products for display device and offers LCD technical consulting to customers to provide them with value-added technical support and integrated solutions.
For How Long HIMX will fight for Profitability? Read This Trend Analysis report
MannKind Corporation (NASDAQ:MNKD) traded up on a volume of 8.29 million, higher than its standard daily volume. Shares have gained 10.13% to $5.22. Over the last twelve months, the stock has gained 91.21% and faced a worst price of $1.82. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.
For How Long MNKD’s Gloss will Attract Investors? Find out via this report
Amarin Corporation plc (ADR) (NASDAQ:AMRN) settled 1.11% higher at $6.37 on above-normal volume of 7.81M shares during the last trading day. The stock has its 12-month high at $12.96 and 52-week low price was $5.12. It traded in a range of $6.30 to $6.54 during the last trading day. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
In the last trading session, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was up on high volume, trading at a volume of 7.76M shares versus its average daily volume of 2.60 million shares. At $23.03, the stock has attained market capitalization of $2.04 billion. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Will ACAD Continue To Move Higher? Find Out Here
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)